Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial

Creative Commons License

O'Donoghue M. L., Fazio S., Giugliano R. P., Stroes E. S. G., Kanevsky E., Gouni-Berthold I., ...More

CIRCULATION, vol.139, no.12, pp.1483-1492, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 139 Issue: 12
  • Publication Date: 2019
  • Doi Number: 10.1161/circulationaha.118.037184
  • Journal Name: CIRCULATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1483-1492
  • Hacettepe University Affiliated: Yes


BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.